26 articles with Novaliq GmbH
The company launched with $6 million in equity funding, which is still open. Betaliq has two compounds in its pipeline, both which use Novaliq’s waterfree EyeSol technology for ophthalmology products.
Novaliq and BLP Management Group Established New Company, Betaliq Inc., to Leverage EyeSol Technology to Treat Glaucoma
Novaliq GmbH, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol® and BLP Management group announce the formation and funding of Betaliq Inc., a new company located in Tampa, Florida.
Novaliq named Finalist in “Clinical Trial Result of the Year” category of the Clinical & Research Excellence Awards CARE 2019
NOV03 is potentially the first drug targeting the key underlying cause of evaporative DED, the leading reason for this undertreated disease that impacts visual function
Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease
The SEECASE trial met its prespecified primary endpoint for both treatment schedules at 8 weeks
Novaliq Announces Positive Topline Results for Its CyclASol® Phase 2B/3 Essence Trial in Patients with Dry Eye Disease
The ESSENCE trial met its primary endpoint at 4 weeks and demonstrated superiority of CyclASol® over vehicle in change from baseline on corneal fluorescein staining
Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Disease
Focus on clinical development and to prepare commercialization of CyclASol® and NOV03
As an emerging leader in the field of ophthalmology, Novaliq is currently pursuing two late-stage clinical trials in the United States.
Novaliq Announces First Patient Enrolled in Its SEECASE Phase II Trial of NOV03 for the Treatment of Dry Eye Disease
Novaliq announced that it has begun randomization of patients in its SEECASE Phase 2 clinical trial for the treatment of dry eye disease (DED).
Novaliq’s NovaTears+Omega-3 Approved in Europe for the Enhanced Treatment of Evaporative Dry Eye Disease
NovaTears+Omega-3 is a technological breakthrough in the treatment of DED.
Novaliq Announces First Patient Randomized in Its ESSENCE Phase 2b/3 Trial of CyclASol for the Treatment of the Signs and Symptoms of Dry Eye Disease
CyclASol potentially overcomes the current intolerability and efficacy profiles due to the benefits of a water-free vehicle and the mechanism of drug delivery.
Novaliq's NovaTears Treatment for Evaporative Dry Eye Disease Launches in New Zealand and Receives Registrational Approval in Australia
NovaTears immediately stabilizes the lipid layer without causing vision blurring.
Novaliq GmbH Strengthens Executive Management Team With The Appointment Of Gabriela Burian, MD, MPH, As Chief Medical Officer
Novaliq GmbH Conducts A First-In-Class Ocular Neuropathic Pain And Anti-Inflammatory Cannabinoid Drug Development Program In Collaboration With University of Cologne, Germany
Novaliq GmbH Announces Licensing Agreement With AFT Pharmaceuticals For The Distribution Of Novatears
Novaliq GmbH Announces Positive Topline Results Of Phase II Clinical Trial Evaluating Cyclasol In Adults With Moderate To Severe Dry Eye Disease
Novaliq GmbH Strengthens Executive Management Team By Appointing Christian Roesky, PhD, As Chief Executive Officer
Novaliq GmbH Announces Last Patient Enrolled In Phase 2 Clinical Trial Of Cyclasol For The Treatment Of Moderate To Severe Dry Eye Disease
Novaliq GmbH Announces Last Patient Enrolled In Phase II Clinical Trial Of Cyclasol For The Treatment Of Moderate To Severe Dry Eye Disease
Novaliq GmbH Begins Phase II Clinical Trial Of Cyclasol For The Treatment Of Moderate To Severe Dry Eye Disease